Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chest. 2021 Oct;160(4):1520-1533. doi: 10.1016/j.chest.2021.05.014. Epub 2021 May 21.
The current nodal classification is unsatisfactory in distinguishing the prognostically heterogeneous N1 or N2 non-small cell lung cancer (NSCLC).
Is the combination of the current N category and the number of metastatic lymph nodes (N-#number) or the combination of the current N category and the ratio of the number of positive to resected lymph nodes (N-#ratio) better than the current N category alone?
We identified 2,162 patients with N1 or N2 NSCLC from the Surveillance, Epidemiology, and End Results database (2004-2016). We classified these patients into three N-#number categories (N-#number-1, N-#number-2a, N-#number-2b) and three N-#ratio categories (N-#ratio-1, N-#ratio-2a, N-#ratio-2b). Lung cancer-specific survival (LCSS) were compared using the Kaplan-Meier method. The prognostic significance of the new nodal classifications was validated across each tumor size category (≤3 cm, 3-5 cm, 5-7cm, >7 cm). Cox proportional hazards regression was used to evaluate the association between each nodal classification and LCSS.
The survival curves showed clear differences between each pair of N-#number and N-#ratio categories. A significant tendency toward the deterioration of LCSS from N-#number-1 to N-#number-2b was observed in all tumor size categories. However, the differences between each pair of N-#ratio categories were significant only in tumors from 3 to 7 cm. Although all three nodal classifications were independent prognostic indicators, the N-#number classification provided more accurate prognostic stratifications compared with the N-#ratio classification and the current nodal classification.
The N-#number classification followed by the N-#ratio classification might be better prognostic determinants than the current nodal classification in prognostically heterogeneous N1 or N2 NSCLC.
目前的淋巴结分类在区分预后不同的 N1 或 N2 非小细胞肺癌(NSCLC)方面并不令人满意。
当前 N 分类与转移淋巴结数量(N-#数量)的组合或当前 N 分类与阳性淋巴结与切除淋巴结比例(N-#比值)的组合是否优于当前 N 分类单独使用?
我们从监测、流行病学和结果数据库(2004-2016 年)中确定了 2162 例 N1 或 N2 NSCLC 患者。我们将这些患者分为三个 N-#数量类别(N-#数量-1、N-#数量-2a、N-#数量-2b)和三个 N-#比值类别(N-#比值-1、N-#比值-2a、N-#比值-2b)。使用 Kaplan-Meier 方法比较肺癌特异性生存率(LCSS)。在每个肿瘤大小类别(≤3cm、3-5cm、5-7cm、>7cm)中验证新淋巴结分类的预后意义。使用 Cox 比例风险回归评估每个淋巴结分类与 LCSS 的相关性。
生存曲线显示每个 N-#数量和 N-#比值类别之间存在明显差异。在所有肿瘤大小类别中,从 N-#数量-1 到 N-#数量-2b 观察到 LCSS 明显恶化的趋势。然而,只有在 3 至 7cm 的肿瘤中,每对 N-#比值类别之间的差异才有统计学意义。尽管所有三种淋巴结分类都是独立的预后指标,但 N-#数量分类比 N-#比值分类和当前淋巴结分类提供了更准确的预后分层。
在预后不同的 N1 或 N2 NSCLC 中,N-#数量分类后接 N-#比值分类可能比当前淋巴结分类更能预测预后。